Outcome of Board Meeting

30 July 2026 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra - Kurla Complex, Mumbai 400 001 Bandra (E), Mumbai 400 051 Scrip Code: 524669 Symbol: HESTERBIO Dear Sir/ Madam: Subject: Outcome of Board Meeting and submission of unaudited Standalone and Consolidated Financial Results for the quarter ended 30 June 2026 This is with reference to our letter dated 23 July 2026 intimating the date of the Board Meeting for consideration of the standalone and consolidated financial results for the quarter ended 30 June 2026. Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the unaudited Standalone and Consolidated Financial Results for the quarter ended 30 June 2026, as recommended by Audit Committee. We attach herewith: 1. The approved unaudited standalone and consolidated financial results and limited review reports 2. A Press Release issued in this regard We will be publishing an extract of the results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board Meeting commenced at 10:30 a.m. (IST) and concluded at 11:07 a.m. (IST). You are requested to take the above information on your record. Sincerely For Hester Biosciences Limited Vinod Mali Company Secretary & Compliance Officer Enclosure: As above STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 Amount in INR Million Quarter Ended Year Ended 30 June 31 March 30 June 31 March Particulars 2026 2026 2025 2026 Audited Unaudited Unaudited Audited (Refer Note 5) Income 1 Revenue from Operations 7 26.60 9 37.13 6 34.90 2 ,921.36 2 Other Income 1 6.83 4 1.79 9 .46 7 6.35 Total income 743.43 978.92 644.36 2,997.71 3 Expenses (a)Cost of material consumed 1 07.92 1 65.14 8 6.82 4 62.23 (b)Purchases of stock-in-trade 5 5.16 9 8.33 8 9.26 3 94.38 (c)Change in inventories of finished goods, ( 3.48) ( 59.98) 1 8.73 ( 36.93) traded goods and work in progress (d)Employee benefits expense 1 31.81 1 39.99 1 32.45 5 31.74 (e)Finance cost 1 3.64 4 0.94 9 .05 7 1.69 (f)Depreciation and amortisation expense 4 9.18 3 6.76 2 1.64 1 02.52 (g)Other expenses 1 91.68 2 79.00 1 83.53 8 45.22 Total expenses 545.91 700.18 541.48 2,370.85 4 Profit before exceptional items and tax 197.52 278.74 102.88 626.86 5 Exceptional items (Refer Note 4) - 69.96 - 69.96 6 Profit before tax 197.52 348.70 102.88 696.82 7 Tax Expense Current tax 4 5.57 7 7.23 1 8.38 1 44.64 Tax Adjustment of earlier years - 0 .01 - 0 .02 Deferred tax 4 .84 7 .62 6 .12 3 1.16 Total tax expense 50.41 84.86 24.50 175.82 8 Profit after exceptional item and tax 147.11 263.84 78.38 521.00 9 Other Comprehensive Income Items that will not be reclassified to Profit or Loss Remeasurement Loss on Defined Benefit - ( 0.67) ( 1.21) ( 0.67) Plans Income tax impact - 0 .17 0 .31 0 .17 Total Other Comprehensive Income - (0.50) (0.90) (0.50) 10 Total Comprehensive Income for the 147.11 263.34 77.48 520.50 period / year 11 Paid-up equity share capital - - - 85.07 12 Other Equity - - - 3 ,766.75 13 Earnings Per Share (Face Value of INR 10 each) (Not Annualised) - Basic & Diluted 17.29 31.01 9.21 61.24 (INR) Notes: 1 The standalone financial results of Hester Biosciences Limited (the “Company”) have been reviewed by the Audit Committeein its meetingheldon 29 July2026 andapprovedbytheBoardofDirectors oftheCompanyin itsmeeting held on 30 July 2026 2 The Statutory Auditors have carried out limited review of these standalone financial results of the Company for the quarter ended 30 June 2026. 3 Following are the details of segment wise revenue, results, segment assets and liabilities: Particulars Quarter Ended Year Ended 30 June 31 March 30 June 31 March 2026 2026 2025 2026 Audited Unaudited Unaudited Audited (Refer note 5) Segment Revenue a.Poultry Healthcare 6 18.16 6 50.72 4 16.68 2 ,061.31 b.Animal Healthcare 1 08.44 2 86.41 2 18.22 8 60.05 Total Revenue from 726.60 937.13 634.90 2 ,921.36 Operations Segment Results a.Poultry Healthcare 2 45.19 2 35.18 8 9.69 5 81.39 b.Animal Healthcare ( 8.47) 1 02.02 3 5.25 1 63.85 Total Segment Results 236.72 337.20 124.94 7 45.24 a.Finance Cost 1 3.64 4 0.94 9 .05 7 1.69 b.Other unallocable 2 5.56 ( 52.44) 1 3.01 ( 23.27) expenditure (Net) Profit before Tax 197.52 348.70 102.88 6 96.82 Segment Assets a.Poultry Healthcare 1 ,237.97 1 ,229.93 2 ,418.32 1 ,229.93 b.Animal Healthcare 6 40.71 6 79.80 5 58.57 6 79.80 Unallocated Assets 3 ,731.66 3 ,663.73 2 ,438.87 3 ,663.73 Total 5 ,610.34 5 ,573.46 5 ,415.76 5 ,573.46 Segment Liabilities a.Poultry Healthcare 8 7.85 1 56.69 1 34.02 1 56.69 b.Animal Healthcare 3 0.59 1 00.48 1 64.87 1 00.48 Unallocated Liabilities 1 ,492.99 1 ,464.47 1 ,648.52 1 ,464.47 Total 1,611.43 1,721.64 1,947.41 1 ,721.64 Note: Unallocated assets comprise Property, Plant and Equipment and other assets pertaining to the BSL-3 and Fill Finish facilities capitalised during the previous year. As these facilities are intended to support operations across multiple segments and the associated economic benefits are expected to be derived jointly by both segments, the related assets have not been specifically allocated to any individual segment and are accordingly disclosed as unallocated assets. 4 During the previous year, the Board of Directors of the Company at its meeting dated 11 March 2026, has approved the divestment of 43.81% equity shareholding out of 54.81% in its subsidiary, Texas Lifescience Private Limited ("TLPL") by way of sale of 21,63,377 Equity Shares of INR 10 each at the price of INR 42.34 per share to existing promoter shareholders of TLPL. TLPL has been ceased to be subsidiary of the company from 27 March 2026 onwards. 5 The figures for quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full year ended 31 March 2026 and the unaudited published year-to-date figures upto 31 December 2025, being the date of the end of the third quarter which were subjected to limited review. For and on behalf of the Board of Directors Rajiv Gandhi Place: Kadi, Mehsana CEO & Managing Director Date: 30 July 2026 DIN: 00438037 Chandulal M. Shah & Co. CHARTERED ACCOUNTANTS N6, 6th Floor, Wing-A, Safal Profltaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015. Tel. : 079-2960 1085 • (M) 90330 34430 • E-mail : cmshah@cmshah.com • Website : www.cmshah.com Independent Auditor's review report on Quarterly Unaudited Standalone Financial Results of Hester Biosciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015, as amended The Board of Directors of Hester Biosciences Limited 1. We have reviewed the accompanying statement of unaudited financial results of Hester • Biosciences Limited for the quarter ended on June 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed u/s 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in accordance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a Report on the Statement based on our revfew. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Ch [Showing first 8,000 characters — download PDF for full document]